JP7799945B2 - 変異型ウイルスタンパク質 - Google Patents

変異型ウイルスタンパク質

Info

Publication number
JP7799945B2
JP7799945B2 JP2020516534A JP2020516534A JP7799945B2 JP 7799945 B2 JP7799945 B2 JP 7799945B2 JP 2020516534 A JP2020516534 A JP 2020516534A JP 2020516534 A JP2020516534 A JP 2020516534A JP 7799945 B2 JP7799945 B2 JP 7799945B2
Authority
JP
Japan
Prior art keywords
seq
protein
amino acid
vsv
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534007A (ja
Inventor
オーレリー アルベルティーニ
イヴ ゴーダン
エレーヌ ロー
ローラ ブロ
ジョヴァン ニコリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60153233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7799945(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2020534007A publication Critical patent/JP2020534007A/ja
Priority to JP2023138247A priority Critical patent/JP2023179436A/ja
Application granted granted Critical
Publication of JP7799945B2 publication Critical patent/JP7799945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020516534A 2017-09-22 2018-09-24 変異型ウイルスタンパク質 Active JP7799945B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023138247A JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306255.5 2017-09-22
EP17306255 2017-09-22
PCT/EP2018/075824 WO2019057974A1 (en) 2017-09-22 2018-09-24 GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138247A Division JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Publications (2)

Publication Number Publication Date
JP2020534007A JP2020534007A (ja) 2020-11-26
JP7799945B2 true JP7799945B2 (ja) 2026-01-16

Family

ID=60153233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516534A Active JP7799945B2 (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質
JP2023138247A Pending JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023138247A Pending JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Country Status (14)

Country Link
US (9) US12091434B2 (https=)
EP (3) EP3684786B1 (https=)
JP (2) JP7799945B2 (https=)
CA (1) CA3076094A1 (https=)
DK (1) DK3684786T3 (https=)
ES (1) ES2991089T3 (https=)
FI (1) FI3684786T3 (https=)
HR (1) HRP20241466T1 (https=)
HU (1) HUE069207T2 (https=)
LT (1) LT3684786T (https=)
PL (1) PL3684786T3 (https=)
PT (1) PT3684786T (https=)
SI (1) SI3684786T1 (https=)
WO (1) WO2019057974A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991089T3 (es) 2017-09-22 2024-12-02 Centre Nat Rech Scient Glicoproteína mutada del virus de la estomatitis vesicular
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
US12061187B2 (en) 2019-05-23 2024-08-13 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
US12311000B2 (en) 2019-08-16 2025-05-27 Mayo Foundation For Medical Education And Research Chimeric vesiculoviruses and methods of use
CN115397838A (zh) * 2020-01-10 2022-11-25 卡罗根公司 溶瘤病毒样囊泡的组合物和使用方法
CN115768784A (zh) * 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
EP4182447A4 (en) * 2020-07-14 2024-10-23 Ichilov Tech Ltd. PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS
MX2023008831A (es) 2021-01-27 2023-10-19 Umoja Biopharma Inc Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
JP2024513973A (ja) * 2021-04-16 2024-03-27 マサチューセッツ インスティテュート オブ テクノロジー 造血幹細胞のウイルスによる標的化
AU2022405508A1 (en) * 2021-12-06 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry
WO2023114884A2 (en) 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
IL291148A (en) * 2022-03-06 2023-10-01 Noga Therapeutics Ltd Lentiviral vectors for in vivo targeting of hematopoietic cells
US20250382586A1 (en) 2022-05-17 2025-12-18 Umoja Biopharma, Inc. Manufacturing viral particles
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
TW202434621A (zh) 2022-11-04 2024-09-01 美商優莫佳生物製藥有限公司 多核苷酸構築體及相關病毒載體及方法
JP2026500897A (ja) 2022-11-04 2026-01-09 ウモジャ バイオファーマ インコーポレイテッド 融合分子を呈示するレンチウイルス粒子およびその使用
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
EP4680620A2 (en) * 2023-03-17 2026-01-21 Kelonia Therapeutics, Inc. In vivo daric
WO2024213019A1 (zh) * 2023-04-10 2024-10-17 深圳市济因生物科技有限公司 突变型vsvg及靶向载体
WO2024216227A1 (en) 2023-04-12 2024-10-17 Vyriad Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry
CN121794390A (zh) * 2023-07-18 2026-04-03 维伟生物技术有限公司 纯化用树脂及其使用方法
WO2025038475A1 (en) * 2023-08-11 2025-02-20 Kelonia Therapeutics, Inc. Compositions for modifying cells
WO2025036498A1 (zh) * 2023-08-16 2025-02-20 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025102013A1 (en) 2023-11-10 2025-05-15 Vyriad Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体
WO2025189142A1 (en) 2024-03-08 2025-09-12 Vyriad Membraned vesicles and purification methods thereof
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025247369A1 (zh) * 2024-05-31 2025-12-04 普米斯生物技术(苏州)有限公司 突变的水泡病毒包膜蛋白及其在慢病毒载体包装中的应用
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2025260074A1 (en) 2024-06-14 2025-12-18 Vyriad Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles
WO2026006203A2 (en) 2024-06-24 2026-01-02 Orbital Therapeutics, Inc. Compositions and methods for making circular rna
WO2026006687A1 (en) 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516607A (ja) 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
JP2005247757A (ja) 2004-03-04 2005-09-15 Nikken Sohonsha Corp 抗ウイルス剤
EP2020444A1 (en) 2007-08-03 2009-02-04 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines
JP2010535495A (ja) 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2016501528A (ja) 2012-12-12 2016-01-21 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517573A (en) * 1999-09-17 2004-02-27 Pro Virus Inc Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)
US8008268B2 (en) * 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
ES2991089T3 (es) * 2017-09-22 2024-12-02 Centre Nat Rech Scient Glicoproteína mutada del virus de la estomatitis vesicular

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516607A (ja) 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
JP2005247757A (ja) 2004-03-04 2005-09-15 Nikken Sohonsha Corp 抗ウイルス剤
EP2020444A1 (en) 2007-08-03 2009-02-04 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines
JP2010535495A (ja) 2007-08-03 2010-11-25 インスティチュート・パスツール レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
JP2016501528A (ja) 2012-12-12 2016-01-21 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法

Also Published As

Publication number Publication date
PT3684786T (pt) 2024-10-30
SI3684786T1 (sl) 2025-03-31
US12030915B2 (en) 2024-07-09
PL3684786T3 (pl) 2024-12-16
US12410215B2 (en) 2025-09-09
JP2023179436A (ja) 2023-12-19
ES2991089T3 (es) 2024-12-02
EP4446337A3 (en) 2025-01-08
US20240092839A1 (en) 2024-03-21
DK3684786T3 (da) 2024-10-28
US20200216502A1 (en) 2020-07-09
US20250171504A1 (en) 2025-05-29
US12264180B2 (en) 2025-04-01
US20240317811A1 (en) 2024-09-26
HRP20241466T1 (hr) 2025-01-03
EP3684786A1 (en) 2020-07-29
LT3684786T (lt) 2024-11-11
EP4442816A3 (en) 2025-01-08
JP2020534007A (ja) 2020-11-26
EP3684786B1 (en) 2024-08-14
US12291551B2 (en) 2025-05-06
US12269848B2 (en) 2025-04-08
US20240327466A1 (en) 2024-10-03
US20260078150A1 (en) 2026-03-19
FI3684786T3 (fi) 2024-11-04
US20240327467A1 (en) 2024-10-03
EP4446337A2 (en) 2024-10-16
WO2019057974A1 (en) 2019-03-28
US20250171505A1 (en) 2025-05-29
EP4442816A2 (en) 2024-10-09
US12410216B2 (en) 2025-09-09
US20240317812A1 (en) 2024-09-26
CA3076094A1 (en) 2019-03-28
HUE069207T2 (hu) 2025-02-28
US12091434B2 (en) 2024-09-17
US12297237B2 (en) 2025-05-13

Similar Documents

Publication Publication Date Title
JP7799945B2 (ja) 変異型ウイルスタンパク質
Paterson et al. Fusion protein of the paramyxovirus SV5: destabilizing and stabilizing mutants of fusion activation
Kretzschmar et al. Membrane association of influenza virus matrix protein does not require specific hydrophobic domains or the viral glycoproteins
JP2017521073A (ja) インフルエンザウイルスワクチンおよびその使用
JP2004512275A (ja) 膜透過性ペプチドおよびその使用
CN108025057A (zh) 稳定化的病毒i类融合蛋白
KR20220057578A (ko) 인플루엔자 바이러스 백신 및 이의 용도
JP6692853B2 (ja) 立体構造的に特異的なウイルス免疫原
HK40117176A (en) Mutated glycoprotein of vesicular stomatitis virus
HK40117175A (en) Mutated glycoprotein of vesicular stomatitis virus
ES2813827T3 (es) Péptidos que incluyen un dominio de unión de la subunidad de la fosfoproteína (P) viral a la nucleoproteína (N0) libre de ARN viral
Tong et al. Oligomerization, secretion, and biological function of an anchor-free parainfluenza virus type 2 (PI2) fusion protein
Maillard et al. Spectroscopic characterization of two peptides derived from the stem of rabies virus glycoprotein
Ye et al. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein
US20260014249A1 (en) Enveloped virus like particles comrising sars-cov-2 s protein
Copeland et al. Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin
Khalifa Understanding Receptor-mediated Spillover of Rabies Virus Across Different Mammalian Hosts
WO2025224710A1 (en) Engineered orthopoxvirus proteins and related methods
WO2025076013A1 (en) Engineered middle east respiratory syndrome proteins and related methods
Shokralla Characterization of the H10/A4 Region of Vesicular Stromatitis Virus G Protein and Effects of H2-H10/A4 Mutations of Fusogenic Functions
within Arenavirus Identification of an N-Terminal Trimeric
Bissonnette Structural and Conformational Requirements of Membrane Fusion Mediated by the Parainfluenza Virus 5 Fusion Protein
NZ752808A (en) Stabilized soluble prefusion rsv f polypeptides

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231107

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211

R150 Certificate of patent or registration of utility model

Ref document number: 7799945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150